Oruka Therapeutics, Inc. Asset Resilience Ratio
Oruka Therapeutics, Inc. asset resilience ratio. Oruka Therapeutics, Inc. (ORKA) has an Asset Resilience Ratio of 53.11% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ORKA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Oruka Therapeutics, Inc. (2005–2025)
Asset resilience ratio of Oruka Therapeutics, Inc. from 2005 to 2025. This chart shows how Oruka Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Read debt load of Oruka Therapeutics, Inc. for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Oruka Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Oruka Therapeutics, Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $605.09 Million | 53.11% |
| Total Liquid Assets | $605.09 Million | 53.11% |
Asset Resilience Insights
- Very High Liquidity: Oruka Therapeutics, Inc. maintains exceptional liquid asset reserves at 53.11% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oruka Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Oruka Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 18.85% |
Oruka Therapeutics, Inc. Asset Resilience Ratio by Year (2005–2025)
Oruka Therapeutics, Inc. asset resilience ratio by year from 2005 to 2025. The table below shows the annual Asset Resilience Ratio data for Oruka Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 59.37% | $290.11 Million | $488.62 Million | -19.93pp |
| 2024-12-31 | 79.31% | $314.07 Million | $396.02 Million | +54.64pp |
| 2017-12-31 | 24.67% | $3.05 Million | $12.37 Million | -31.21pp |
| 2016-12-31 | 55.88% | $13.76 Million | $24.63 Million | +1.60pp |
| 2007-12-31 | 54.28% | $65.51 Million | $120.68 Million | +3.96pp |
| 2006-12-31 | 50.32% | $92.79 Million | $184.41 Million | +20.17pp |
| 2005-12-31 | 30.15% | $32.57 Million | $108.05 Million | -- |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-… Read more